Goldman Sachs Maintains Buy on Mylan Inc. (MYL)

Goldman Sachs is out with its report this morning on Mylan Inc. MYL, maintaining Buy after meeting with management.

In a note to clients, Goldman Sachs writes, "Near-term path remains attractive with 1Q a low hurdle in our view and a more active launch pipeline in 2011 likely to instill further confidence in Street numbers that we think move higher in the outer years. No change to our EPS or $28 price target – reaffirm CL Buy."

Shares of MYL closed Tuesday at $22.84.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsGoldman SachsHealth CaremylanPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!